{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/leg-cramps/prescribing-information/quinine/","result":{"pageContext":{"chapter":{"id":"6abcb54e-aaf5-5ec2-81c1-541a1da196ac","slug":"quinine","fullItemName":"Quinine","depth":2,"htmlHeader":"<!-- begin field 909c4d32-c480-4072-bd00-a88700be4811 --><h2>Quinine</h2><!-- end field 909c4d32-c480-4072-bd00-a88700be4811 -->","summary":"","htmlStringContent":"<!-- begin item f670ea51-6d94-4951-b9f0-a88700be45b0 --><!-- end item f670ea51-6d94-4951-b9f0-a88700be45b0 -->","topic":{"id":"7c418711-124c-5406-ac4f-2a486df1abe5","topicId":"6f757429-c10d-418e-a5e9-0b258476ea47","topicName":"Leg cramps","slug":"leg-cramps","lastRevised":"Last revised in February 2018","chapters":[{"id":"026868e3-f884-5f67-8045-13c0f83d836f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a8b89203-f7e6-55c6-8499-d3f2260976bd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"88e9d094-58ee-5897-bf60-ffc12dc6061d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"296fff6d-1600-50fc-81e6-83f99a31aad3","slug":"changes","fullItemName":"Changes"},{"id":"c1f278c6-1c88-5aa5-972f-49fdffcebae8","slug":"update","fullItemName":"Update"}]},{"id":"27a17af0-725d-5555-9115-d9e8f4711096","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b7516453-7b49-588b-80b7-8b3fe90ff33f","slug":"goals","fullItemName":"Goals"},{"id":"3f5d1491-8151-5fa9-865f-aee578f051b8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"eb3b3762-f70b-54a3-9c3a-9d797363b71f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"06439565-50c4-5473-bf02-baafd44ec160","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4d9d0fb5-d506-5af2-872e-003a0ecc0649","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a91d2f0-8d87-53e6-9a80-0cea60ccd9a8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"739a22b8-1121-5fb1-a424-e9f57e0cfedb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"571b4a72-201f-555a-9221-4bacf3a2d1f9","slug":"definition","fullItemName":"Definition"},{"id":"cd8d8cc0-b161-50db-b67c-306b66edc872","slug":"prevalence","fullItemName":"Prevalence"},{"id":"afbb1f18-d7b2-564e-8106-7838a14394fb","slug":"causes","fullItemName":"Causes"},{"id":"a52b2c56-6ce3-52bf-8f9f-1cb10ea2e741","slug":"complications","fullItemName":"Complications"}]},{"id":"26782059-5aea-5e9d-8c1c-0adace8fbbeb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"75e93903-9269-5f1b-9ce2-3978baeea25d","slug":"assessment-for-underlying-cause","fullItemName":"Assessment for underlying cause"},{"id":"b396e15e-66c9-5c95-88bb-8bb821ec965d","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7980d599-9313-5d1d-af70-d8c5ef81ba75","fullItemName":"Management","slug":"management","subChapters":[{"id":"4ab5e71d-9e1e-5c56-9162-d97eb574e3b9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"aff3dacc-44d7-5b4b-b70c-2aa2a4295e7f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6abcb54e-aaf5-5ec2-81c1-541a1da196ac","slug":"quinine","fullItemName":"Quinine"}]},{"id":"8c88921f-e6c5-5253-9fc9-5d10da8fdc9f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"9b600958-78b3-5983-9ff5-f581baad9f19","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"980efbe7-8f1f-5747-b78e-2504f1412cac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c5b0abda-4cf4-52a9-890b-e3a6d714e374","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"da265fe5-9c75-59f8-8cdc-7fecd1cf5349","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"63763678-188c-5227-ad8e-ef422ea8a467","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"57ef6db4-f684-57fd-8d87-5767e6ead638","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8ef69487-3b7f-5909-a225-d8a2040693a8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"aff3dacc-44d7-5b4b-b70c-2aa2a4295e7f","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ff43f7e2-5878-5c55-94e4-5c3366332b03","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1d4c3f23-1a8b-433c-8b12-a88700be82b6 --><h3>What are the contraindications and cautions when prescribing quinine?</h3><!-- end field 1d4c3f23-1a8b-433c-8b12-a88700be82b6 -->","summary":"","htmlStringContent":"<!-- begin item 6cbf45fa-a0b8-4445-8bfc-a88700be8129 --><!-- begin field 4c4586d8-18bf-484c-b0aa-a88700be82b6 --><ul><li>Do not prescribe quinine for people who have had an adverse reaction to quinine previously (including to tonic water).</li><li>Quinine is also contraindicated for people with:<ul><li>Haemoglobinuria.</li><li>Optic neuritis.</li><li>Tinnitus.</li><li>Myasthenia gravis (quinine can cause severe respiratory distress and dysphagia in this group).</li></ul></li><li>Pregnant women should not be prescribed quinine to treat leg cramps. Breastfeeding women should not receive quinine unless the benefits outweigh the risk as quinine is excreted in breastmilk.</li><li>Prescribe quinine with caution in older people and anyone with:<ul><li>Cardiac disease; risk factors for QT prolongation (including medicines); atrial fibrillation, conduction defects, heart block — quinine can exacerbate conduction defects.</li><li>Electrolyte disturbance.</li><li>Glucose-6-phosphate dehydrogenase deficiency — the risk of haemolytic anaemia may be increased when taking quinine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-cramps/references/\">MHRA, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-cramps/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-cramps/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-cramps/references/\">MHRA, 2017</a>] </p><!-- end field 4c4586d8-18bf-484c-b0aa-a88700be82b6 --><!-- end item 6cbf45fa-a0b8-4445-8bfc-a88700be8129 -->","subChapters":[]},{"id":"5376d277-bd40-5daa-9511-401b5e18cf4f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a00bc490-e0d0-4a8d-b9d9-a88700bea2c4 --><h3>What are the adverse effects of quinine?</h3><!-- end field a00bc490-e0d0-4a8d-b9d9-a88700bea2c4 -->","summary":"","htmlStringContent":"<!-- begin item 487148e4-72e5-43d8-b2fd-a88700be9ee5 --><!-- begin field 76dae519-89f1-475f-bceb-a88700bea2c4 --><ul><li>Quinine is extremely toxic in the event of an overdose and can cause life-threatening adverse effects (such as arrythmias, convulsions, respiratory depression, and renal failure) and irreversible loss of vision.</li><li>Cinchonism can occur in overdose, but has also been reported after normal doses of quinine — symptoms include nausea, vomiting, convulsions, headache, tinnitus, deafness, vasodilation, and visual disturbance.</li><li>In high doses, quinine can be teratogenic and may cause miscarriage.</li><li>Other reported adverse effects include:<ul><li>Haematological: thrombocytopenia, intravascular coagulation, pancytopenia.</li><li>Neurological: coma, vertigo, agitation, confusion.</li><li>Dermatological: flushing, angio-oedema, rashes, pruritus, hypersensitivity.</li><li>Musculoskeletal: weakness, aggravation of myasthenia gravis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-cramps/references/\">MHRA, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-cramps/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-cramps/references/\">BNF 74, 2017</a>] </p><!-- end field 76dae519-89f1-475f-bceb-a88700bea2c4 --><!-- end item 487148e4-72e5-43d8-b2fd-a88700be9ee5 -->","subChapters":[]},{"id":"d574642f-763d-5c1b-af3c-94d98f3a0a83","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 52508c8d-eaa7-49d6-8879-a88700beb9da --><h3>What drug interactions are associated with quinine?</h3><!-- end field 52508c8d-eaa7-49d6-8879-a88700beb9da -->","summary":"","htmlStringContent":"<!-- begin item 733bb195-7509-4579-aacc-a88700beb852 --><!-- begin field 6ffcba49-aca7-447b-a970-a88700beb9da --><ul><li>The potential for quinine toxicity is increased by drugs which inhibit CYP3A4, including azole antifungals and HIV protease inhibitors.</li><li>Serum levels of quinine may be reduced by CYP3A4 inducers such as rifampicin, carbamazepine, and phenytoin.</li><li>Quinine can increase the plasma concentration of the following drugs:<ul><li>Flecainide.</li><li>Digoxin and cardiac glycosides.</li><li>Mefloquine.</li><li>Amantadine.</li></ul></li><li>Concurrent use of quinine and:<ul><li>Drugs which increase the QT interval (for example amiodarone, clarithromycin, citalopram, lithium, moxifloxacin, ondansetron, pimozide, ranolazine, sotalol, thioridazine) — increases the risk of ventricular arrhythmias.</li><li>Anticoagulants — may cause hypoprothrombinaemia and enhance anticoagulant effects.</li><li>Hypoglycaemics — increases the risk of hypoglycaemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-cramps/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-cramps/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-cramps/references/\">MHRA, 2017</a>]</p><!-- end field 6ffcba49-aca7-447b-a970-a88700beb9da --><!-- end item 733bb195-7509-4579-aacc-a88700beb852 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}